Somewhat Favorable News Coverage Somewhat Unlikely to Affect Ophthotech Corporation (OPHT) Stock Price
Media stories about Ophthotech Corporation (NASDAQ:OPHT) have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ophthotech Corporation earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.2244604518056 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Ophthotech Corporation (OPHT) Lifted to “Strong-Buy” at Zacks Investment Research (americanbankingnews.com)
- Gabelli Weighs in on Ophthotech Corporation’s FY2017 Earnings (OPHT) (americanbankingnews.com)
- ETFs with exposure to Ophthotech Corp. : November 10, 2017 (finance.yahoo.com)
- Notable Watch List: Ophthotech Corporation, (NASDAQ: OPHT), Avery Dennison Corporation, (NYSE: AVY), Pinnacle … – Stocks In The News (press release) (tradingnewsnow.com)
- Captivating Stocks-:- Ophthotech Corporation (NASDAQ:OPHT), Energy Transfer Equity, LP (NYSE:ETE), Teligent, Inc … – Market Breaking Point (press release) (journalfinance.net)
Ophthotech Corporation (OPHT) opened at $3.20 on Tuesday. Ophthotech Corporation has a fifty-two week low of $2.24 and a fifty-two week high of $40.34. The company has a market cap of $103.07, a PE ratio of 1.82 and a beta of 1.40.
A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Ophthotech Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price objective on shares of Ophthotech Corporation in a report on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Ophthotech Corporation from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective on the stock in a report on Monday. Twelve analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Ophthotech Corporation presently has a consensus rating of “Hold” and a consensus target price of $8.31.
Ophthotech Corporation Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Stock Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related stocks with our FREE daily email newsletter.